CLOVER CORPORATION LIMITED (CLV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CLV - CLOVER CORPORATION LIMITED

FNArena Sector : Health & Nutrition
Year End: July
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.02
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.10

21 Sep
2023

0.000

OPEN

$1.10

0.000

HIGH

$1.10

15,160

LOW

$1.07

TARGET
$1.35 22.7% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
EBO . EXL . MCP . SIG .
FNARENA'S MARKET CONSENSUS FORECASTS
CLV: 1
Title FY21
Actual		 FY22
Actual		 FY23
Forecast		 FY24
Forecast
EPS (cps) xxx 4.3 4.0 xxx
DPS (cps) xxx 1.5 1.0 xxx
EPS Growth xxx 18.8% - 6.8% xxx
DPS Growth xxx 50.0% - 33.3% xxx
PE Ratio xxx N/A 27.5 xxx
Dividend Yield xxx N/A 0.9% xxx
Div Pay Ratio(%) xxx 35.0% 25.0% xxx

Dividend yield today if purchased 3 years ago: 0.73%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.36

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 05/04 - ex-div 0.75c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201720182019202020212022
EPS Basic xxxxxxxxxxxxxxx4.3
DPS All xxxxxxxxxxxxxxx1.5
Sales/Revenue xxxxxxxxxxxxxxx70.7 M
Book Value Per Share xxxxxxxxxxxxxxx37.9
Net Operating Cash Flow xxxxxxxxxxxxxxx6.6 M
Net Profit Margin xxxxxxxxxxxxxxx10.09 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202020212022
Return on Capital Employed xxxxxxxxxxxxxxx11.75 %
Return on Invested Capital xxxxxxxxxxxxxxx9.89 %
Return on Assets xxxxxxxxxxxxxxx8.42 %
Return on Equity xxxxxxxxxxxxxxx11.75 %
Return on Total Capital xxxxxxxxxxxxxxx15.05 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx3.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201720182019202020212022
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx10 M
Total Debt xxxxxxxxxxxxxxx12 M
Goodwill - Gross xxxxxxxxxxxxxxx2 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx10 M
Price To Book Value xxxxxxxxxxxxxxx2.84

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201720182019202020212022
Capex xxxxxxxxxxxxxxx1.6 M
Capex % of Sales xxxxxxxxxxxxxxx2.26 %
Cost of Goods Sold xxxxxxxxxxxxxxx49 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx10 M
Research & Development xxxxxxxxxxxxxxx2 M
Investments - Total xxxxxxxxxxxxxxx12 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

UBS

16/03/2023

3

Downgrade to Neutral from Buy

$1.35

22.73%

Despite a 1H sales beat of 26% by Clover compared to the UBS forecast, the broker lowers its rating to Neutral from Buy.

The analyst awaits further evidence of the company's ability to monetise its market opportunities and is cautious over timing uncertainties of customers achieving the GB Standard licensing requirements.

Guobiao Standards (GB) are food safety standards issued by the Standardised Administration of China (SAC).

FY23 sales guidance of $80-90m implies to the broker a smaller 2H skew than usual. The $1.35 target price is unchanged.

FORECAST
UBS forecasts a full year FY23 dividend of 1.00 cents and EPS of 4.00 cents.
UBS forecasts a full year FY24 dividend of 2.00 cents and EPS of 6.00 cents.
Access Stockbroker Research History >

CLV STOCK CHART

FNArena News on CLV

1
Weekly Ratings, Targets, Forecast Changes – 17-03-23

Mar 20 2023 - Weekly Reports
2
FNArena Corporate Results Monitor – 17-03-2023

Mar 17 2023 - Australia
3
FNArena Corporate Results Monitor – 26-09-2022

Sep 26 2022 - Australia
4
Weekly Ratings, Targets, Forecast Changes – 16-09-22

Sep 19 2022 - Weekly Reports
5
Weekly Ratings, Targets, Forecast Changes – 18-03-22

Mar 21 2022 - Weekly Reports

Latest Health & Nutrition News

1
Sigma’s Win Not Neccessarily Ebos’ Loss

Jun 14 2023 - Small Caps
2
Sigma Healthcare: Brokers Wary

Mar 31 2022 - Australia
3
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
4
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
5
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps
6
Nine Ignored Companies Now Worth A Look

Sep 23 2020 - FYI
7
Next Week At A Glance – 14-18 Sep 2020

Sep 11 2020 - Weekly Reports
8
Sigma Farewells API, Heralds New Contract

Dec 17 2019 - Australia
9
Blackmores: Hopes Pinned On Restructuring

Nov 01 2019 - Australia
10
Blackmores Peps Up Its Strategy For China

Apr 17 2019 - Australia